ABSTRACT

This brief report documents the safety and efficacy of high-dose tigecycline as a salvage-therapy in a case series of five patients with serious central nervous system (CNS) rocky mountain spotted fever (RMSF). These seriously ill patients were unable to take any oral drug therapy, parenteral doxycycline was unavailable and absorption of oral doxycycline was a concern in these critically ill patients. As far as we know, we report the successfull use of tigecycline for the treatment of rickettsial meningitis for the first time in Italy. We suggest more studies on tigecycline in severe CNS infections from 

*Rickettsia* species and multi-drug resistant bacteria, especially the use of tigecycline at higher than standard doses in these life-threatening infectious diseases.

Keywords: Tigecycline; *Rickettsia*; Rickettsiosis; *Rickettsia rickettsii*; Rocky mountain spotted fever

INTRODUCTION

*Rickettsia* is a group of vector-borne organisms that cause acute febrile illnesses that continue to be a major health problem in tropical and temperate parts of the world. Patients present with febrile exanthems and visceral involvement. Rickettsial infection may present as meningitis and should be included in the differential diagnosis in endemic countries. Meningoencephalitis due to Rocky Mountain Spotted Fever (RMSF) may be a life-threatening infection, and high morbidity and mortality make early recognition and empiric treatment critical [1]. Rickettsial encephalitis, is characterised by confusion and obtundation due to increased intracranial pressure and has been associated with a worse prognosis. In general, rickettsial meningitis behaves like a viral meningitis but responds to doxycycline instead of symptomatic therapy with the dosing and length of therapy dependent on the specific causative organism. When affected individuals are experiencing nausea or vomiting, or are seriously ill, medications may be administered by infusion intravenously (iv). However, in Italy, where RMSF is endemic, iv doxycycline is not available. Another tetracycline-like parenteral antibiotic, tigecycline, is available in Italy, but its effectiveness against *R.rickettsii* is unknown. Tigecycline showed in vitro susceptibility to *Coxiella* species, *Rickettsia* species, and multidrug-resistant *Neisseria gonorrhoeae* strains. The aim of this retrospective study was to evaluate the safety and the efficacy of tigecycline in a case series of patients with RMSF of the
Ethics statement
The institutional review board (IRB) authorized the collection of data, after the acquisition of informed consent was obtained by all participants in this study. Data were collected between January 1, 2016 and December 31, 2020 in medical records.

Conflict of Interest
No conflict of interest.

Author Contributions
Conceptualization: AM. Data curation: SG. Formal analysis: SG, VV. Investigation: SG, VV, MVM. Methodology: AM, FU. Project administration: AM, FU. Resources: AM, FU. Software: AM, FU. Supervision: AM, FU. Validation: AM, FU. Writing - original draft: AM. Writing - review & editing: AM.

Central nervous system (CNS). This brief report documented the safety and efficacy of high dose tigecycline as a salvage-therapy in serious CNS rickettsial infections.

CASE SERIES

Herein, we report a case series of five (3 males, 2 females; the mean ages were 67.64 ± 9.26 years) patients with RMSF of the CNS (Table 1). Data were collected between January 1, 2016 and December 31, 2020 in medical records. Five of 22 patients with RMSF presented with meningitis and/or encephalitis syndromes. Charlson comorbidity index was 4.40 ± 2.05, APACHE II score was 15 ± 4.95. Comorbidities included: diabetes mellitus (3), chronic obstructive pulmonary disease (3), chronic heart failure (2). In the years before symptom onset or diagnosis, no patient received an organ transplant. No patient removed a tick from their body. At the time of diagnosis, no patient was immunocompromised due to medical condition (s) or treatment (s) (such as one of the following: chemotherapy for current illness, human immunodeficiency virus (HIV), anti-rejection drugs post-transplant, corticosteroids >14 days, rheumatoid arthritis with use of immunomodulatory). No patient donated blood in the 30 days prior to symptom onset and no patient was blood donor identified during an investigation into a transfusion-associated infection. The diagnosis of rickettsial meningitis was based on clinical features and on cerebral spinal fluid (CSF) findings. Focal neurologic signs were rare; CSF profiles were similar to those of viral meningitis. Neurological features were typically non-focal, with headache, neck stiffness, photophobia, confusion and reduction in conscious level. One patient had cerebellitis. Other major organ involvement (renal, liver, or lungs) occurred in all five patients. Three patients were immediately intubated and placed on mechanical ventilation; initial laboratory investigations showed severe acidosis. Chest radiography, head computer tomography and magnetic resonance imaging were normal. The finding of abnormalities on electroencephalogram (EEG) during the course of aseptic meningitis was considered to be indicative of parenchymal brain involvement. CSF examination showed a slight pleocytosis, the protein content was raised, and glucose was normal. CSF and blood cultures were negative. Investigation for herpesvirus, enterovirus, arbovirus, Borrelia and Mycobacterium tuberculosis were negative. Serological blood studies including HIV, venereal disease research laboratory, Mycoplasma, Brucella and Bartonella excluded acute infection. The diagnosis was confirmed by serology (immunofluorescence assay) that showed a seroconversion, with an eightfold increase of IgG antibodies for R. rickettsii in 2 weeks (with titres of 128 and 1,024, respectively). Tigecycline was administered at a high dose (100 mg every 12 hours, after a 200 mg loading dose) for a median treatment duration of 7.5 days, with progressive improvement in all patients. Thirty-day crude mortality, defined as the incidence of deaths from any cause within the approximately 30-day follow-up duration, was chosen as the primary outcome variable for defining antimicrobial effectiveness All patients evolved favourably with remission of symptoms, and they hadn’t sequelae. There were no patients requiring tigecycline discontinuation or dose reduction because of adverse events. The defervescence mean time was 3.94 days (± 0.96 SD). Treatment was completed with use of 5 - 10 days of oral doxycycline as patients were able to take the tablets orally. Tigecycline was well tolerated at a higher than standard dose. High-dose tigecycline was not associated with 30-day crude mortality, adverse drug reactions or abnormal laboratory measures.
DISCUSSION

Treatment of rickettsial meningitis may be challenging, as the antimicrobial options are restricted [2]. A tetracycline should be regarded as the drug of choice due to its high efficacy, low toxicity, and oral doxycycline represents the most effective drug, but during severe life-threatening disease, iv therapy may be recommended [2]. Unfortunately, iv formulations of doxycycline are not always available, therefore it would be necessary to determine some new alternative parenteral agents. However, the Centers for Disease Control and Prevention did not definitively recommend alternative therapy should doxycycline be entirely unavailable [3]. In Italy, where RMSF is endemic, iv doxycycline is not available for use. Tigecycline, another tetracycline-like parenteral antibiotic, is available in Italy, but its effectiveness against \textit{R. rickettsii} is unknown. Tigecycline, a tetracycline derivative, belongs to a novel class of antibiotics known as the glycylcyclines, developed in response to the emergence of resistant organisms. They are structurally related to tetracyclines and, like the classic tetracyclines, act through inhibition of protein translation in bacteria. In vitro and in vivo studies have shown that tigecycline possesses broad-spectrum antibacterial activity. In addition, the intracellular penetration of tigecycline and its high capability to remain accumulated inside may play a critical role in inhibiting the intracellular multiplication of bacteria, thus tigecycline can be used to treat intracellular bacteria [4].

Tigecycline is widely used to treat complicated intra-abdominal infections, skin-structure infections and community-acquired pneumonia with a good safety and tolerability profile. Different studies provide information regarding the use of tigecycline in various clinical

---

**Table 1. Epidemiologic and clinical characteristics of the patients with rocky mountain spotted fever-related meningo-encephalitis treated with tigecycline**

| Number of laboratory-confirmed cases | 5 |
|--------------------------------------|---|
| Sex, Patient age (years), Race       | 3 males, 2 females; the mean ages were 67.64 ± 9.26 years, caucasian |
| Life in endemic area, Contact with dog’s ticks | 100%, 40% |
| Onset between May and October        | 70% |
| Clinical Criteria                    |   |
| Fever higher than 39°C               | 100% |
| Eschar “Tache noire”                 | 40% |
| Maculopapular or purpuric eruption   | 100% |
| Headache                             | 100% |
| Myalgia                              | 100% |
| Altered sensorium                    | 100% |
| Signs of meningial irritation        | 100% |
| Did the patient experience any severe complications in the clinical course of this illness? | 100% |
| Acute respiratory distress syndrome (ARDS) | No |
| Disseminated intravascular coagulation (DIC) | No |
| Meningitis/encephalitis              | 100% |
| Unspecific Biological Criteria       |   |
| Increased inflammatory indices (C-reactive protein, procalcitonin) | 100% |
| Leukocyte count \(<4 \times 10^9\) cells/L, Neutrophils \(>70\)% | 60%, 70% |
| Normochromic normocytic anemia (Hemoglobin levels \(<110\) g/L) | 80% |
| Platelet count \(<150 \times 10^9\) cells/L, Platelet count \(<100 \times 10^9\) cells/L | 100%, 60% |
| Alanine aminotransferase levels \(>40\) U/L | 60% |
| Bacteriological Criteria            |   |
| Isolation of \textit{Rickettsia rickettsii} from blood and/or cerebrospinal fluid | Not available |
| Detection of \textit{Rickettsia rickettsii} in skin biopsy using immunofluorescence assays | Not available |
| Serological Criteria (Immunofluorescence) |   |
| Serum with IgG \(1 : 128\) and IgM \(>1 : 64\) | 100% |
| 4-fold increase in titer in a double serum sample within 2 weeks | 100% |
| Cerebrospinal fluid examination      |   |
| Did the patient die from this illness or complications of this illness? | Slight pleocytosis, a raised protein content, and a normal glucose value |
| Did the patient die from this illness or complications of this illness? | There was no mortality in our study |
conditions, however clinical experience in patients with meningitis is very limited. Despite its high efficacy against multi-drug-resistant (MDR) pathogens, tigecycline is currently not recommended in cases of meningal infections, based on data showing modest penetration to the CSF [5-7]. Tigecycline weakly penetrates CSF and the CSF-to-serum concentration ratio ranged from 0.106 - 0.066 [6] to 0.242 - 0.049 [5] and 0.302 0.185 [7] in previous studies.

Tigecycline usually displays good antibacterial activity against resistant gram-negative and gram-positive bacteria, as do many antimicrobial drugs according to synergy, but due to the lack of penetration to the CNS, their serum concentration in the CSF is only 11% [5-7]. Despite the low concentrations reached by tigecycline in CSF compared to minimum inhibitory concentration, some reports describe a positive evolution of the therapy of CNS infections from multidrug-resistant organisms with tigecycline (Table 2) [8]. It could be hypothesized a drug accumulation in polymorphonuclear cells and then be delivered to the site of infection in higher than anticipated concentrations, or the presence of minor sub-inhibitory effects [7].

Although penetration into the CNS is minimal (around 11%), intraventricular therapy (IVT) with tigecycline could be of help in managing and could be considered in patients with post-neurosurgical CNS infections from MDR bacteria (Table 3) [9-13]. The use of multi-route [continuous ventricular irrigation (CVI), and intraventricular administration (IVT)] of tigecycline is effective and should be considered in managing lifethreatening MDR intraventricular infections. The use of multi-route (CVI and IVT) tigecycline and IVT colistin for MDR/XDR ventriculitis is effective, and those treatment options should be considered as a valuable therapy in managing these life-threatening intraventricular infections [11, 13].

In a rabbit model of penicillin-resistant pneumococcal meningitis, a single dose of tigecycline showed adequate CSF penetration, and it was found to be effective in reducing colony counts in CSF in combination with vancomycin [14].

Tigecycline resulted effective against R. rickettsii in cell culture and in an animal model of RMSF [15], it possesses enhanced in vitro activity against C. burnetii [16] and against Rickettsia japonica [17], and it sufficiently suppressed the activity of Orientia tsutsugamushi in vitro [18].

Patients with scrub typhus–induced acute kidney injury and renal transplantation-derived infection due to Ehrlichia chaffensis effectively treated with tigecycline were retrospectively identified (Supplementary Table 1) [19, 20]. To the best of our knowledge, this is the first report of tigecycline therapy for CNS infections caused by R. rickettsii. In Italy the formulation of doxycyclin for intravenous use is not available, furthermore our patients with CNS rickettsiosis were not being able to take doxycycline by mouth in the acute phase of illness. Although the number of patients presented in our report is limited, we underline the safely and efficacy use of tigecycline as a salvage-therapy in patients with CNS rickettsiosis (Supplementary Table 2). Physicians should be aware of the possibility of using high dose tigecycline for the early treatment of CNS infection due to RMSF, in patients who cannot take oral doxycyclin, should intravenous doxycyclin be entirely unavailable, in cases in which parenthernal therapy is needed.
# Table 2. Characteristics of patients previously reported with CNS infection treated with intravenous tygecycline

| Characteristic | Patient 1 (Ray L, et al) | Patient 2 (Jaspan HB, et al) | Patient 3 (Emiroglu M, et al) | Patient 4 (Danandche P, et al) | Patient 5 (Guo W, et al) | Patient 6 (Tutuncu EE, et al) | Patient 7 (Tutuncu EE, et al) | Patient 8 (Wadi JA, et al) | Patient 9 (Gordon NC, et al) | Patient 10 (Shrestha GS, et al) | Patient 11 (De Pascale G, et al) | Patient 12 (Kooli I, et al) |
|---------------|--------------------------|-----------------------------|-------------------------------|-------------------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|-----------------------------|
| Age, y/sex    | 38y/F                    | 21-month/F                  | 5-month/M                     | 42y/M                         | 48y/M                    | 48y/M                       | 32y/M                       | 44y/F                       | 75y/M                       | 42y/M                         | 24y/M                       |                             |
| Country       | USA                      | USA                         | Turkey                        | Vancomycin-                 | None                      | Ventriculo-               | NA                          | Improved                    | IV, 50 mg/q12h               | NA                          | Italy                        |                             |
| Underlying disease(s) | Middle cerebral artery strokes | USA | Leukemia, peripheral blood stem cell transplant, muromonab | Ventriculoperitoneal shunt was placed for posthemorrhagic hydrocephalus | Sickle cell disease | Severe traumatic brain injury | Turkey | Turkey | Multiple injuries to the head, face and extremities | Polimixin | ≍ | Acinetobacter sp. |
| Primary infection | Postoperative cerebritis | Meningitis | Ventriculo-peritoneal shunt meningitis | Meningitis | Ventriculitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical meningitis |
| Organism(s)   | MRAB                     | Vancomycin-resistant Enterococcus fecium (VRE) | MDRKP                         | MDRKP                        | MRAB                      | MRAB                       | MDR Acinetobacter sp.      | MRAB                        | MRAB                        | MRAB                         | MRAB                        | MRAB                        |
| Tigecycline MIC (mg/L) | 0.75 (CSF)               | 0.325 (CSF)                | ≤0.5 μg/mL (CSF - E-test)      | 1.0 mg/L (E-test)            | ≤1 μg/mL (CSF)          | 0.38 μg/ml (CSF) by Etest (AB Biodisk, Solna, Sweden) | 0.38 μg/ml (CSF) by Etest (AB Biodisk) | NA                          | 2 mg/L                       | NA                          | 3.2 mg/L by Etest            |
| Side effects  | None                     | Mildly elevated hepatic transaminases (Drug-drug interactions) | None                           | None                         | None                      | None                       | None                        | None                        | None                        | None                          | None                          | None                        |
| TGC           | Tigecycline              | Daptomycin (IVT) + Tigecycline | Meropenem (60 days) + Tigecycline | Tygecycline, at twice the daily dose (100 mg every 12 hours) | Polimixin (IVT, IV) + Tigecycline | IV, 50 mg/q12h             | IV, 50 mg/q12h               | Tigecycline monotherapy. | Tigecycline IV, 50 mg/q12h | IV, 50 mg/q12h               | IV, 50 mg/q12h               | (check please)               |
| LOT (Days)    | 18 days                  | 14 days                     | 20 days                       | = 21 days                    | ≥ 21 days                 | ≥ 21 days                  | = 21 days                   | 34 days                     | NA                          | 14 days                       | NA                          | 21 days                     |
| Co-administered antibiotics | NA                      | DAP (IVT)                   | MEM, 60 days                  | Polimixin (IVT, IV)          | Netilmicin IV, (400 mg/ q24h), MEM IV, (2g/q24h) | Netilmicin IV, (400 mg/ q24h), MEM IV, (2g/q24h) | NA                          | MEM, 5 days                  | CST IV, 2 million IU/q8h | NT, 0.2 million IU/q24h | 150,000 IU/ q24h              |
| Days to CSF sterilization | 12                      | 2                           | 6                             | 3                             | 5                         | 21                        | 12                           | NA                          | 7                            | 20                           | 23                           |
| Outcome       | Failed to achieve clinical response | Improved                   | Improved                      | Improved                     | Improved                   | Improved                   | Improved                     | Improved                     | Improved                     | Improved                     | Improved                     | Improved                     |

CNS, central nervous system; F, female; M, male; CSF, cerebrospinal fluid; EVD, external ventricular drainage; MRAB, multidrug-resistant Acinetobacter baumannii; MDRKP, multi-drug resistant Klebsiella pneumoniae; MDR, multi drug resistant; MIC: mean inhibitory concentration; NA, not available; CST, colistin; TGC, tygecycline; IVT, intraventricular therapy; IV, intravenous; LOT, length of treatment; DAP, daptomycin; MEM, meropenem.
### Table 3. Characteristics of adults previously reported with CNS infection treated with intraventricular tigecycline

| Characteristic | Patient 1 (Lauretti L, et al) | Patient 2 (Fang JQ, et al) | Patient 3 (Long W, et al) | Patient 54 (Tsolaki V, et al) | Patient 5 (Tsolaki V, et al) | Patient 6 (Tsolaki V, et al) | Patient 7 (Wu Y, et al) |
|----------------|-------------------------------|-----------------------------|---------------------------|--------------------------------|-------------------------------|-----------------------------|--------------------------|
| Age, y/sex     | 22y/M                         | 50y/M                       | 55y/M                     | 55y/F                          | 50y/M                        | 48y/M                       | 67y/M                    |
| Country        | Italy                         | China                       | India                     | Greece                          | Greece                        | Greece                      | China                    |
| Underlying disease(s) | A giant pituitary adenoma, post-resection CSF leak | Craniocerebral injury | Intracerebellar hemorrhage, CSF leak, hydrocephalus, EVD | Aneurysmal subarachnoid hemorrhage | Intraventricular mass resection, cerebral edema, hemorrhage, EVD | Cerebral haemorrhage, EVD |
| Primary infection | Post-neurosurgical meningitis | Post-neurosurgical meningitis | Post-neurosurgical ventriculitis | Post-neurosurgical VM | Post-neurosurgical VM | Post-neurosurgical VM | Post-neurosurgical meningitis |
| Organism(s)    | XDRAB                        | MDRAB                       | MDRAB                     | MDRAB                          | MDRAB                        | MDRKP                       | MDRKP                    |
| Tigecycline MIC (mg/L) | 2 μg/ml                      | 2 μg/ml                     | 16 μg/mL                  | 2 μg/ml                        | 1 μg/ml                      | NR                          | NR                       |
| Tigecycline concentrations (mg/L) | NR                            | NR                          | NR                        | NR                             | NR                           | NR                          | NR                       |
| Side effects   |                               |                             |                           | TGC, IV/CVI/IVT                | IV, 100 mg/q12h, IV, 2 mg/(q24h - q12h) | IV, 100 mg/q12h, IV, 2 mg/q12h | IV, 100 mg/q12h, IV, 2 mg/q12h |
| TGC, IV/CVI/IVT | IV, 100 mg/q12h, IV, 2 mg/(q24h - q12h) | IV, 100 mg/q12h, IV, 2 mg/q12h | IV, 100 mg/q12h, IV, 2 mg/q12h | IV, 100 mg/q12h, IV, 2 mg/q12h | IV, 100 mg/q12h, IV, 2 mg/q12h | IV, 100 mg/q12h, IV, 2 mg/q12h |
| LOT (Days)     | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT | IV, 14 days; 1 month from the restart of the IVT |
| Co-administered antibiotics | CST IVT, 120,000/q12h Meropenem IV, 2 g/q8h Vancomycin IV, 1 g/q12h | Cefoperazone-sulbactam IV, 3 g/q12h | Cefoperazone-sulbactam IV, 2 g/q8h | IV TGC, 14 days IV TGC, 15 days IV TGC, 15 days IV TGC, 15 days IV TGC, 15 days IV TGC, 15 days IV TGC, 15 days |
| Outcome | Improved | Improved | Improved | Improved | Improved | Improved | Improved |
| Days to CSF sterilization | 75 | 14 | 12 | 4 days of IVT | 5 days of IVT | 3 days of IVT | 42nd day with IVT TGC 10 mg (gradually escalating dose) |

CNS, central nervous system; M, male; F, female; CSF, cerebrospinal fluid; EVD, external ventricular device; VM, ventriculitis and meningitis; XDRAB, extensive drug resistant Acinetobacter baumannii; MDRAB, multidrug-resistant Acinetobacter baumannii; MDRKP, multi-drug resistant Klebsiella pneumoniae; NR, not reported; IV, intravenous; IVT, intra-ventricular therapy; CVI, continuous ventricular irrigation; LOT, length of treatment; TGC, tygecicline; TMP/SMX, trimethoprim-sulfamethoxazole; COL, colimycin.

### SUPPLEMENTARY MATERIALS

#### Supplementary Table 1
Characteristics of patients previously reported with intracellular infections treated with tygecycline

Click here to view

#### Supplementary Table 2
Clinical data and outcome of 5 patients with CNS rickettsiosis treated with tigecycline

Click here to view
REFERENCES

1. Bradshaw MJ, Byrge KC, Ivey KS, Pruthi S, Bloch KC. Meningoencephalitis due to spotted fever rickettsioses, including rocky mountain spotted fever. Clin Infect Dis 2020;71:188-95. PUBMED | CROSSREF

2. Yaghoubi S, Zekiyo AO, Krutova M, Gholami M, Kouhsari E, Shoileh M, Ghafouri Z, Maleki F. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis 2021:1-20. PUBMED | CROSSREF

3. Centers for Disease Control and Prevention (CDC). Nationwide shortage of doxycycline: Resources for providers and recommendations for patient care. Available at: http://emergency.cdc.gov/han/han00349.asp. Accessed 7 August 2015.

4. Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhartd O, Derendorf H. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 2009;48:575-84. PUBMED | CROSSREF

5. Rodvold KA, Gottfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EI. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9. PUBMED | CROSSREF

6. Pallotto C, Fiorio M, D’Avolio A, Sgrelli A, Baldelli F, Di Perri G, De Socio GV. Cerebrospinal fluid penetration of tigecycline. Scand J Infect Dis 2014;46:69-72. PUBMED | CROSSREF

7. Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010;44:582-6. PUBMED | CROSSREF

8. Kooli I, Brahimi HB, Kilani M, Gannouni C, Aouam A, Toumi A, Loussaief C, Hattab MN, Chakroun M. Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline. J Glob Antimicrob Resist 2016;5:62-3. PUBMED | CROSSREF

9. Lauretti L, D’Alessandris QG, Fantoni M, D’Inzeo T, Fernandez E, Pallini R, Scoppettuolo G. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg 2017;127:370-3. PUBMED | CROSSREF

10. Fang YQ, Zhan RC, Jia W, Zhang BQ, Wang JJ. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore) 2017;96:e7703. PUBMED | CROSSREF

11. Long W, Yuan J, Liu J, Wu M, Chen X, Peng G, Wu C, Zhang C, Wang X, Zhao W, Liu Q. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: A case report and review of literature. Front Neurol 2018;9:518. PUBMED | CROSSREF

12. Tsolaki V, Karvouniaris M, Manoulakas E, Kotliu P, Karadontas V, Fotakopoulos G, Zakyntinos E, Makris D. Intraventricular CNS treatment with colistin-tigecycline combination: A case series. J Crit Care 2018;37:338-41. PUBMED | CROSSREF

13. Wu Y, Chen K, Zhao J, Wang Q, Zhou J. Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother 2018;30:49-52. PUBMED | CROSSREF

14. Fang GD, Weiss WJ, Scheld WM. Comparative efficacy of GAR-936, a novel glycylcycline alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae experimental meningitis in rabbits. Abstract 868. Program and abstracts of the 40th Interscience Conference on Antimicrobials and Chemotherapy (ICAAC), September 17–20, 2000, Toronto, Ontario, Canada. Washington, DC: ASM Press; 2000;51. PUBMED | CROSSREF

15. Blanton LS, Wilson NM, Quade BR, Walker DH. Susceptibility of Rickettsia rickettsii to tigecycline in a cell culture assay and animal model for rocky mountain spotted fever. Am J Trop Med Hyg 2019;101:1091-5. PUBMED | CROSSREF

16. Spyradaki I, Psaroulaki A, Vranakis I, Tselsentis Y, Gikas A. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. Antimicrob Agents Chemother 2009;53:2690-2. PUBMED | CROSSREF
17. Satoh M, Kato H, Takayama-Ito M, Ogawa M, Ando S, Saijo M. *In vitro* evaluation of minimum inhibitory concentration of several antibacterial agents against *Rickettsia japonica* using a plaque reduction assay system. J Infect Chemother 2019;25:917-9. 
[PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3947/ic.2021.0070)

18. Lee SM, Kwon HY, Im JH, Baek JH, Hwang SS, Kang JS, Chung MH, Lee JS. *In vitro* activity of tigecycline against *Orientia tsutsugamushi*. Yonsei Med J 2016;57:1034-7. 
[PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3947/ic.2021.0070)

19. Kuo MJ, Kuo CP, Chu SY, Tarng DC, Tseng WC. The case a 71-year-old man with fever, acute kidney injury, and a black crustaceous lesion. Kidney Int 2019;95:239-40. 
[PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3947/ic.2021.0070)

20. Sachdev SH, Joshi V, Cox ER, Amoroso A, Palekar S. Severe life-threatening *Ehrlichia chaffeensis* infections transmitted through solid organ transplantation. Transpl Infect Dis 2014;16:119-24. 
[PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.3947/ic.2021.0070)